Working together from lab to bedside, dedicating ourselves to finding ways to make a difference in an individual’s life.
Aspiring to improve health in our patients through new precision therapeutics for cancer uncovered by data-driven drug discovery and development.
Providing the hope of potential treatment options to patients and families at all turns.
H3 Biomedicine, the U.S.-based precision oncology research and development subsidiary of Eisai Co., Ltd., is focused on advancing drugs from bench to bedside. Uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics, H3 Biomedicine is developing a pipeline of highly targeted medicines that have the potential to impact the future of cancer care and treatment.Learn More
Unlocking cancer genomics, real-world patient data, and biomarkers in clinical research to deliver on the promise of precision oncology medicine.